Keyword: Cambridge, Massachusetts
Synlogic CEO Dr. Aoife Brennan shares what the company learned from the failure of its ammonia program and what it means for Synlogic’s future.
Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.
The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.
Sherlock Biosciences, maker of CRISPR-based field tests, is partnering up with Mologic to develop a suite of “instrument-free” molecular diagnostics.
Six months after getting off a $50 million series A round, Atlas Venture-incubated startup Dyne has hired its full-time leader.
Drug discovery company Sygnature Discovery is moving its U.S. office to Kendall Square, the heart of the Cambridge–Boston biotech hub in Massachusetts.
Joichi Ito has been forced out as head of the Media Lab at MIT as well as from biotech builder PureTech’s board after ties to Jeffrey Epstein were uncovered.
Charles River has penned “early 2020” for the opening of its Charles River Accelerator and Development Lab (aka CRADL) in South San Francisco.
Eisai opened its first startup incubator as part of its new center focused on exploring the genetic links to dementia and potential immunotherapies.
The investment vehicle, the largest ever raised by Third Rock, will support investments in 10 to 12 companies.